Despite incorporating a limited number of genes, most of the genes included were tightly linked to potential FDA-approved clinical actionability, such as BRAF mutations c.1799T>A (p.V600E) in melanoma regarding dabrafenib, trametinib or vemurafenib treatments, and EGFR tyrosine-kinase domain mutations in NSCLC for afatinib, erlotinib, gefitinib and osimertinib therapies (Hovelson et al., 2015; Paasinen-Sohns et al., 2017). This evidence concerns the gene EGFR and melanoma.